Abstract | BACKGROUND: CASE PRESENTATION: A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent surgery followed by adjuvant radiation therapy. Multiple metastases to bone were documented one year later. Since the original tumor was strongly HER2/neu positive by immunohistochemistry, the patient was treated with trastuzumab, capecitabine, and zoledronic acid. He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution. Continued treatment has resulted in maintenance of disease control for over 2 years. CONCLUSION:
|
Authors | Elad Sharon, Ronan J Kelly, Eva Szabo |
Journal | Head & neck oncology
(Head Neck Oncol)
Vol. 2
Pg. 12
(May 26 2010)
ISSN: 1758-3284 [Electronic] England |
PMID | 20504363
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Deoxycytidine
- Capecitabine
- Receptor, ErbB-2
- Trastuzumab
- Fluorouracil
|
Topics |
- Adenoma, Pleomorphic
(drug therapy, enzymology)
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Capecitabine
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Fluorouracil
(administration & dosage, analogs & derivatives)
- Humans
- Male
- Middle Aged
- Receptor, ErbB-2
(biosynthesis)
- Salivary Gland Neoplasms
(drug therapy, enzymology)
- Trastuzumab
|